Abiratas 250mg Tablet

The majority of the side effects experienced after taking Abiratas 250mg Tablet do not need any medical help as they do not appear with time. The human body starts adapting to the medicine. Consult your doctor if they become unmanageable.

Common side effects of Abiratas Tablet are mentioned below:
Vomiting and Nausea
Muscle twitches & cramps
Fatigue
Anemia 
Frequent urinary tract infection
Diarrhea & Indigestion
High blood pressure
Cough
Swelling in legs or feet
Chest pain

Irregular heartbeat

bone fractures
blood in urine

Abiratas 250mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Abiratas 250mg Tablet is an anticancer medication used for treating prostate cancer. This medicine works by preventing androgen (male hormone) production in males. It inhibits an enzyme termed as CYP17 which is responsible for the production of androgen. Androgen is a hormone that helps in the multiplication of cancer cells. This process slows down the growth rate of cancerous cells in prostate cancer.

It is advised not to miss any scheduled dosage of Abiratas 250mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Abiratas 250mg Tablet is usually taken with another medication known as prednisolone to avoid the unwanted side effects.

It is advised to always use effective birth control methods to avoid pregnancy while undergoing treatment with Abiratas 250mg Tablet.

It is crucial to monitor your liver function, blood pressure, and the level of potassium in your blood regularly when undergoing treatment with Abiratas 250mg Tablet.

Acharya M, Bernard A, Gonzalez M, Jiao J, De Vries R, Tran N. (2024). Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol. 69(6):1583-90.
Charles J. Ryan et al. (2025). Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. J Clin Oncol 28, 1481-1488(2010).
Goyal J, Antonarakis ES.(2024).Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol 23(7):1-14.
Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. (2024). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 28(9):1481-8.
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. (2024). Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 36(14):1389-1395.